


**Sudden cardiac death  
early post MI:  
Are we barking up the  
wrong tree?**

**Jeffrey Goldberger, MD  
Director, Cardiac Electrophysiology  
Research  
Professor of Medicine**


# Disclosures

- u **Research/Lectures - Boston Scientific, Medtronic.  
St. Jude**

**Can we identify patients  
after acute MI who are at  
high risk for SCD and  
need early intervention?**



Monthly rate of SCD 1.4% 0.5% 0.27% 0.18% 0.14%



# Questions

- u **After an MI, when do VT/VF events occur?**
- u **Is better definition of the substrate for VT/VF likely to result in better risk stratification?**

“The electrophysiologic substrate for VT gradually develops in the first 2 weeks after MI, and once established, appears to remain indefinitely”


Zipes, Jalife: Cardiac Electrophysiology:  
From Cell to Bedside: 2004

# Defibrillator in Acute MI Trial

- u N=674, 76% male, age  $62 \pm 11$  years
- u 6-40 days after acute MI (mean 18 days)
- u LVEF  $\leq 35\%$  (actual  $28 \pm 5\%$ )
- u SDNN  $\leq 70$  ms or mean RR  $\leq 750$  ms
- u 87% on  $\beta$ -blockers
- u 95% on ACE inhibitors
- u 78% on lipid lowering agents



# DINAMIT



# Study Hypothesis



ImmEDIATE Risk-Stratification Improves Survival (IRIS) study

High-risk patients after acute MI will show a better survival when treated early with an ICD compared to patients receiving optimal medical therapy (OMT) alone

# Methods Used for Risk-Stratification




**Criterion I** Left ventricular ejection fraction (EF)  $\leq$  40% on day 5–31, together with heart rate  $\geq$  90 beats per minute (bpm) on the first available electrocardiogram

*and/or*

**Criterion II** Non-sustained ventricular tachycardia at a rate  $\geq$  150 bpm during Holter-ECG on day 5-31


# All Cause Mortality




## No. at Risk

Control group	453	410	380	336	307	267	230	187	151	118	79	49	36
ICD group	445	390	366	338	303	253	207	163	137	106	78	48	40


# EF $\leq$ 40%, Heart Rate $\geq$ 90 bpm



# Rapid Non-sustained Ventricular Tachycardia




# Sudden Death After MI



# MADIT II

MI  $\geq$  1 month  
LVEF  $\leq$  30%



MI Time (mo)	HR	95% CI	P
<18	0.98	0.52–1.84	0.95
18–59	0.52	0.26–1.05	0.07
60–119	0.50	0.28–0.91	0.02
120	0.62	0.36–1.08	0.09

HR indicates hazard ratio for ICD vs conventional therapy.



# Explaining the Acute MI - SCD Paradox

QUARTERLY FOCUS ISSUE: HEART RHYTHM DISORDERS

## **Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction**

The Results Are Not Shocking

Jeffrey J. Goldberger, MD, Rod Passman, MD, MSCE


*Chicago, Illinois*

- u Pathogenesis of SCD immediately after acute MI is different than later post-MI
- u Different risk stratifiers are needed after acute MI
- u ICD implantation after acute MI may have deleterious effects


JACC 2009; 54:2001-5

# Time Course of Structural, Functional and Electrical Changes


- 134 asymptomatic post-MI patients
- MUGA, RH cath, ECG, Holter
  - 4 days
  - 4 weeks
  - 6 months
  - 1.5 years
  - 3-7 years




# Time Course of Structural, Functional and Electrical Changes



**Monthly rate of SCD** 1.4% 0.5% 0.27% 0.18% 0.14%




# Results of Autopsy Adjudication in 105 Clinical Cases of SCD



# Explaining the Acute MI - SCD Paradox

- u Pathogenesis of SCD immediately after acute MI is different than later post-MI
- u **Different risk stratifiers are needed after acute MI**
- u ICD implantation after acute MI may have deleterious effects

# BEta-blocker STRategy Plus ICD Trial



# Early Risk Stratification after STEMI

**Table 1. Baseline Patient Characteristics by Group\***

Characteristic	Group 1 (n=574)	Group 2 (n=83)	Group 3 (n=32)	<i>P</i>
Men, n (%)	453 (79)	62 (75)	30 (94)	0.077
Age, mean±SD, y	60±13	58±11	57±11	0.224
Diabetes mellitus, n (%)	149 (26)	13 (16)	11 (34)	0.225
Hypertension, n (%)	320 (56)	32 (39)	14 (44)	0.007
Hyperlipidemia, n (%)	332 (58)	40 (48)	22 (69)	0.097
Family history, n (%)	308 (54)	41 (49)	20 (63)	0.482
History of coronary artery disease, n (%)	130 (23)	16 (19)	10 (31)	0.405
Previous coronary artery surgery, n (%)	25 (4)	2 (2)	2 (6)	0.598
Previous PCI, n (%)	54 (9)	5 (7)	6 (19)	0.113
Current smoker, n (%)	237 (41)	45 (54)	11 (34)	0.089
Previous stroke, n (%)	24 (4)	4 (5)	1 (3)	0.919
Q-wave development, n (%)	348 (61)	55 (66)	20 (63)	0.643

\*Group 1, LVEF >40% and no EPS; group 2, LVEF ≤40%, no VT, and no ICD; group 3, LVEF ≤40%, VT induced, and ICD.



# Early Risk Stratification after STEMI

Zaman et al Circ 2009

762 patients with STEMI tested with 1° PCI

32 (4%) excluded as LVEF not assessed

730 (96%) patients with LVEF assessed

156 patients with LVEF  $\leq$  40%

41 (26%) excluded as EPS not performed

115 patients with EPS performed

Group 1 N=574

LVEF > 40%

Discharged with no ICD

Group 2 N=83

No VT induced

Discharged with no ICD

Group 3 N=32

VT induced

ICD inserted in 28


Appropriate ICD activations in 6 due to VT

Kaplan Meier 1 year mortality = 3.0%

Kaplan Meier 1 year mortality = 3.0%

Kaplan Meier 1 year mortality = 5.6%

# Kaplan-Meier estimates of the probability of survival according to study group



# Questions

- u **After an MI, when does substrate for VT/VF form? When do VT/VF events occur?**
- u **Is better definition of the substrate for VT/VF likely to result in better risk stratification?**

# GUSTO 2-YEAR SURVIVAL

**EF > 40%**

N=1701

2 year mortality 6.8%

Total # of deaths 116

EF > 40% n = 1701


**EF ≤ 40%**

N=242

2 year mortality 25.2%

Total # of deaths 61


EF ≤ 40% n = 242




EF > 40%	60	11	6	4	2	6	0	6	7	4	2	5	3
EF ≤ 40%	36	5	4	3	2	1	0	2	2	2	2	1	1
Cumulative Deaths per interval													

# Canine Model


Extent of myocardial scar is related to inducibility of VT




# Sustained Monomorphic VT: Reentry in an infarct scar




**Channel / Isthmus**




# Sustained Monomorphic VT: Reentry in an infarct scar



**Channel / Isthmus**









# Infarct Morphology Identifies Patients With Substrate for Sustained VT


## u 48 pts with CAD undergoing EPS

- 21 not inducible      EF  $35 \pm 3\%$
- 18 MVT                      EF  $28 \pm 2\%$
- 9 PVT/VF                      EF  $34 \pm 6\%$

## u MRI results


- |           |                       |                              |
|-----------|-----------------------|------------------------------|
| - 21 NI:  | Inf mass $14 \pm 3\%$ | SA $93 \pm 14 \text{ cm}^2$  |
| - 18 MVT: | Inf mass $26 \pm 3\%$ | SA $172 \pm 15 \text{ cm}^2$ |
|           | $<0.009$              | $<0.002$                     |

# ROC Curves




# Virtual Electrophysiologic Testing Using Cardiac MRI

- 3D ceMRI to reconstruct LV and define scar
- At sites of normal LV - normal conduction
- At sites of scar - no conduction
- At border zone - slowed conduction
- Model propagation



# VT Induction Example



# **Can we identify patients after acute MI who are at high risk for SCD and need early intervention?**

- u ? Lower risk of arrhythmic SCD than previously thought**
- u EF is NOT a good discriminator**
- u EPS has promising potential**
- u Novel imaging approaches may be complementary**